Breaking Down Pacific Shuanglin Bio-pharmacy Co., LTD Financial Health: Key Insights for Investors

Pacific Shuanglin Bio-pharmacy's financial picture is a study in contrasts: revenue slid to 986 million yuan in H1 2025 (down 13.2% YoY) after nine‑month sales of 1,618.15 million yuan versus 1,890.27 million a year earlier, following a 2024 full‑year revenue of 2.65 billion yuan (+14.0% YoY) and a volatile growth history (‑3.18% in 2023, +21.98% in 2022); profitability shows trailing‑twelve‑month net income of 357.18 million yuan for the nine months to Sept 30, 2025, a gross margin of 46.07% and net margin of 23.49% with EPS of 0.60 yuan, yet operating cash flow is slightly negative at ‑2.23 million yuan and free cash flow is a notable -477.22 million yuan; balance sheet strength is evident in a low debt‑to‑equity of 0.13 with total debt of 1.03 billion yuan and a net cash position of 202.74 million yuan, current and quick ratios of 2.93 and 1.56 respectively, and interest coverage of 37.80, while market valuation sits at a 15.49 billion yuan market cap with trailing P/E of 26.97, forward P/E 13.49, P/S 6.40 and P/B 1.90; risks include regulatory warnings over disclosure and negative cash flows during an aggressive capacity expansion (Phase II additions totalling 3,100‑ton capacity across subsidiaries) even as growth catalysts - historic 2020-2024 CAGR in sales of 26.1% and net profit CAGR of 42.11%, inclusion of its IVIG (pH4) in clinical protocols, strategic raw‑plasma partnerships, and analyst forecasts of ~29.5% annual earnings growth and ~20.4% revenue growth - set the stage for a detailed read.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Revenue Analysis

Pacific Shuanglin reported mixed revenue momentum across 2022-2025, with notable volatility driven by capacity expansion and short-term supply disruptions from subsidiaries.

• Operating revenue in H1 2025: 986 million yuan (YoY decline of 13.2%).
• Revenue for the nine months ending 30 Sep 2025: 1,618.15 million yuan vs. 1,890.27 million yuan in the same period of 2024.
• Full-year 2024 revenue: 2.65 billion yuan, up 14.00% from 2.33 billion yuan in 2023.
• Revenue growth rates: 2022 +21.98%, 2023 -3.18%, 2024 +14.00%.
• Revenue per employee: 950,660 yuan based on 2,635 employees.

• Primary driver of the H1/9M 2025 revenue decline: capacity expansion at wholly-owned subsidiaries Guangdong Shuanglin and Paisfeico, which temporarily lowered product supply and sales.
• Operational implication: short-term revenue compression in 2025 while fixed assets and production capacity are brought online-potentially paving the way for higher future throughput.
• Efficiency metric: revenue per employee of 950,660 yuan highlights scale relative to workforce size (2,635 employees).

For context on the company's stated strategic priorities and long-term direction, see: Mission Statement, Vision, & Core Values (2026) of Pacific Shuanglin Bio-pharmacy Co., LTD.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Profitability Metrics

Pacific Shuanglin Bio-pharmacy's recent profitability profile shows a mix of solid margins and decelerating absolute earnings. Key figures for the trailing periods highlight margin strength but lower net income year-over-year.

• Net income (nine months ending Sept 30, 2025): ¥357.18 million, down from ¥542.73 million in the same period prior year.
• Trailing twelve-month (TTM) net profit margin: 23.49%.
• TTM earnings per share (EPS): ¥0.60.
• Return on equity (ROE): 7.07%; Return on assets (ROA): 4.01%.
• Gross margin: 46.07%; Operating margin: 25.05%; Profit margin (net): 23.49%.
• EPS repeated (TTM): ¥0.60.

Selected implications and focus areas for investors:

• Margin structure (46.07% gross, 25.05% operating, 23.49% net) indicates efficient cost control and healthy pricing power despite lower absolute net income.
• Decline in nine-month net income (¥357.18M vs ¥542.73M) warrants review of revenue trends, one-off items, and R&D or SG&A changes driving year-over-year earnings pressure.
• ROE of 7.07% and ROA of 4.01% are moderate-monitor capital allocation, leverage, and asset utilization to assess potential uplift.
• EPS (¥0.60 TTM) provides a baseline for valuation multiples; compare to peers and historical EPS growth to gauge fairness of current market pricing.

For broader corporate context, see: Mission Statement, Vision, & Core Values (2026) of Pacific Shuanglin Bio-pharmacy Co., LTD.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Debt vs. Equity Structure

Pacific Shuanglin's capital structure is equity-dominant, with limited reliance on external debt. Key metrics show a conservative leverage profile and robust short-term liquidity, supporting operational flexibility and lower financial risk.

• Debt-to-equity ratio: 0.13 - low leverage, equity largely finances the business.
• Total debt: ¥1.03 billion.
• Net cash position: ¥202.74 million (cash minus debt), indicating the company holds more liquid assets relative to interest-bearing liabilities.
• Interest coverage ratio: 37.80 - strong ability to service interest expenses from operating profit.
• Current ratio: 2.93 - healthy short-term liquidity to cover liabilities due within a year.
• Quick ratio: 1.56 - sufficient immediate liquidity excluding inventories.
• Total equity (book value): ¥8.02 billion; book value per share: ¥8.44.

Implications for investors:

• Low leverage (0.13) reduces bankruptcy risk and interest burden volatility.
• Net cash position and high interest coverage (37.80) signal resilience to profit swings and capacity to fund operations or strategic investments without new debt.
• Strong current and quick ratios (2.93 and 1.56) indicate working capital sufficiency; the company can meet near-term obligations while maintaining operational liquidity.
• Substantial book equity (¥8.02 billion) and ¥8.44 book value per share provide a conservative balance-sheet cushion relative to debt.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Liquidity and Solvency

• Current ratio: 2.93 - strong short-term coverage of liabilities.
• Quick ratio: 1.56 - sufficient immediate liquidity excluding inventories.
• Interest coverage ratio: 37.80 - robust ability to service interest expense.
• Net cash position: ¥202.74 million - positive overall cash buffer.
• Operating cash flow: ¥-2.23 million - slight negative cash generation from operations.
• Free cash flow: ¥-477.22 million - significant negative free cash flow after investments.

• Implications for investors:
  • Solid liquidity ratios and high interest coverage reduce short-term solvency risk.
  • Negative operating and free cash flow warrant monitoring of cash generation and capex funding.
  • Positive net cash provides a buffer while operations are adjusted.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Valuation Analysis

• Valuation context: Trailing P/E of 26.97 vs. forward P/E of 13.49 signals expected earnings growth or near-term profitability improvement priced into the stock.
• Balance of multiples: Elevated EV/EBITDA (21.13) and EV/EBIT (25.21) suggest market premium relative to operating cash flow and EBIT; P/B of 1.90 indicates moderate premium to book value.
• Revenue and sales perspective: P/S of 6.40 reflects investor willingness to pay above current sales-important for pharma companies with pipeline-driven upside.
• Income return: Dividend yield of 2.44% plus an earnings yield of 3.67% provide partial cash-return context versus growth expectations.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) Risk Factors

• Regulatory compliance and disclosure deficiencies: the Shanxi Securities Regulatory Commission issued a warning after the company signed supplementary agreements with clients without proper filing, resulting in identified lapses in internal control and inaccurate information disclosure. This increases the risk of further regulatory sanctions, investor trust erosion, and the potential need for remediation costs.
• Operational disruption from capacity expansion: management attributes a year‑on‑year decline in revenue in H1 2025 to capacity expansion at wholly‑owned subsidiaries that temporarily reduced product supply. Reduced near‑term output can depress topline and margin recovery until new capacity is fully commissioned and ramped up.
• Negative operating cash flow: reported operating cash flow for recent periods is negative, indicating cash outflows from core operations and potential liquidity pressures if operating performance does not improve or external financing is constrained.
• Negative free cash flow: after capital expenditures to expand capacity, free cash flow is negative, signaling challenges in generating surplus cash post‑investment and increasing reliance on financing to fund working capital and growth projects.
• Interest coverage vs. cash generation mismatch: while the company's interest coverage ratio is relatively high-suggesting current earnings can meet interest obligations-the combination of negative operating and free cash flows could impair the firm's practical ability to service debt if earnings weaken or capital needs rise.
• Low leverage but limited flexibility: the company's debt‑to‑equity ratio is low, indicating modest financial leverage today; however, persistent negative cash flows may erode that cushion and constrain future borrowing capacity or force asset sales or equity raises under unfavorable terms.

• Immediate investor considerations:
  • Monitor quarterly cash‑flow trajectories and management commentary on capacity ramp timelines.
  • Track any follow‑up regulatory filings, rectifications, or penalties stemming from the supervisory warning.
  • Assess financing plans (debt vs. equity) should negative free cash flow persist.
• Red flags to watch:
  • Continued negative operating cash flow beyond the stated expansion period.
  • Deterioration in interest coverage or a rising debt‑to‑equity ratio driven by new borrowing.
  • Further disclosure irregularities or governance failures revealed in audit reports or regulator updates.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Growth Opportunities

• Capacity expansion: Phase II of Pacific Shuanglin (1,600 tpa) and Guangdong Shuanglin (1,500 tpa) have been recently commissioned, adding 3,100 tons/year aggregate plasma-derived product capacity.
• Historical growth (2020-2024): Sales revenue CAGR of 26.1% and net profit CAGR of 42.11% through the 14th Five‑Year Plan period.
• Product validation: Intravenous immunoglobulin (pH4) inclusion in COVID-19 treatment protocols across several medical institutions, demonstrating clinical acceptance and demand elasticity.
• Raw material scaling: Strategic cooperation and restructuring with Xinjiang Deyuan Biological Engineering Co., Ltd. to increase raw plasma supply and reduce procurement volatility.

• Capacity-led margin leverage: With 3,100 tpa additional capacity, incremental fixed-cost absorption should improve gross margin and operating leverage as utilization ramps.
• Demand catalysts: COVID-era inclusion of pH4 IVIG in treatment plans indicates persistent clinical demand and potential formulary expansion across hospitals and specialty centers.
• Vertical integration & supply security: Cooperation with Xinjiang Deyuan targets larger owned/controlled plasma volumes, lowering raw-material cost volatility and supporting stable gross margins.
• Forecast implication: Management and analysts project revenue to grow ~20.4% annually and earnings ~29.5% annually, supporting EPS growth of ~29.2% p.a. and a projected ROE of ~11.3% in three years.